ZBTB1’s role in aging blood cells and clonal blood disorders
Official title: The Role of Zbtb1 in Normal and Clonal Hematopoiesis
Funded at Sloan-Kettering Inst Can Research · NIH-11452321 · Data updated 2026-11-12
A physician-researcher is studying how age-related changes in blood stem cells and a gene called ZBTB1 may give certain mutant clones in the blood a survival advantage, potentially leading to conditions like AML and MDS.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $169,020 |
| NIH project number | 1K08HL183856-01A1 |
| Project ID | NIH-11452321 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 60 and older with or at risk for clonal hematopoiesis or related blood disorders may be eligible through future translational efforts.
✕Less likely to help
People without clonal hematopoiesis or related risk factors may not directly benefit from this specific mechanistic study.
What this research studies
This project explores how aging affects blood stem cells and how ZBTB1, a key transcription factor, may drive clonal hematopoiesis and the progression to blood cancers. Using advanced single-cell sequencing, the team will examine epigenetic changes and how they alter ZBTB1 expression in normal and DNMT3A-mutant stem cells. The work aims to identify how ZBTB1 interacts with metabolic regulators and whether these pathways could be targeted to prevent malignant transformation. If successful, the findings could inform new strategies to monitor or intervene in individuals at risk for AML/MDS due to clonal hematopoiesis.
Why it matters
Potential benefit: Better understanding of who is at risk and new avenues to prevent progression to AML/MDS could improve early detection and someday patient outcomes.
How similar studies have gone: Previous work shows that ZBTB1 and epigenetic regulation influence HSC function, supporting the potential for meaningful insights, though direct clinical translation is still developing.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Elias, Harold — Sloan-Kettering Inst Can Research
- Study coordinator: Elias, Harold
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.